Voyager Therapeutics appoints Nathan Jorgensen as CFO effective July 8, 2024

Voyager Therapeutics, Inc.

Jorgensen, 47, previously CFO of Vor Biopharma; will report to CEO Alfred Sandrock.
Annual base salary of $480,000; target annual bonus of 40% of base salary.
Inducement equity grants: option to purchase 200,000 shares (4-year vest) and RSU for 80,000 shares (3-year vest).
Severance: 12 months base salary plus pro-rata bonus and COBRA on termination without cause or for good reason within 12 months of a sale event.
Employment at-will; standard non-compete and non-solicitation provisions.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nathan Jorgensen

Chief Financial Officer

VYGR · Voyager Therapeutics, Inc.

Effective: 2024-07-08
Filed: June 13, 2024, 7:59 PM ET

On June 11, 2024, Voyager Therapeutics, Inc. (the “Company”) and Nathan Jorgensen entered into an employment agreement (the “Jorgensen Agreement”), pursuant to which Dr. Jorgensen agreed to serve as the Chief Financial Officer of the Company, with his employment to commence no later than July 8, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nathan Jorgensen was appointed as Chief Financial Officer at Voyager Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On June 11, 2024, Voyager Therapeutics, Inc. (the “Company”) and Nathan Jorgensen entered into an employment agreement (the “Jorgensen Agreement”), pursuant to which Dr. Jorgensen agreed to serve as the Chief Financial Officer of the Company, with his employment to commence no later than July 8, 2024

View on SEC.gov

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-071048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.